The "one-stop" hybrid coronary revascularization combines minimally invasive direct coronary artery bypass (MIDCAB) and PCI to be performed in the hybrid operating suite, an enhanced operating room equipped with radiographic capability. This study is to compare 1-year clinical outcomes of "one-stop" hybrid coronary revascularization with percutaneous coronary intervention (PCI) in selected patients with multivessel coronary artery disease.
Rationale and purpose of this study: "One-stop" (also named simultaneous) hybrid coronary revascularization has emerged as a novel, safe and feasible minimally invasive approach in selected patients with multivessel coronary artery disease (CAD). The benefits of "one-stop" hybrid procedure compared with conventional PCI are unclear, however. This study is a single center randomized clinical trial to compare the safety and efficacy of "one-stop" hybrid procedure with conventional PCI in the treatment of selected patients with multivessel CAD requiring revascularization with suitable coronary anatomy. Sample size: We examined the results of SYNTAX trial and of the hybrid procedures published previously. The 1-year MACCE rate (the primary endpoint) is estimated as being 18% for PCI/stenting and 8% for the hybrid group. The sample calculated for this trial is 480 patients. Design/Methodology: Trial design: A single center randomized clinical trial comparing "one-stop" hybrid procedure versus conventional PCI with SES in 480 patients with suitable anatomy who need revascularization. Intervention: Patients will be randomized to undergo either "one-stop" hybrid procedure or conventional PCI with SES. Randomization: Patients will be evaluated by both a cardiac surgeon and an interventional cardiologist. After obtaining informed written consent, patients will be randomized to receive "one-stop" hybrid procedure or conventional PCI with SES. An expertise-based randomization will be used. The data adjudicators will be blinded to the study. Due to the nature of this study, the operating surgeons, cardiologists, anesthetists, other operative room staff, and ICU staff will not be blind in this study. Study intervention: Candidates will be randomized to receive "one-stop" hybrid procedure or conventional PCI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB. Device: Polymer-based Sirolimus-Eluting Stents (SES).
Polymer-based Sirolimus-Eluting Stents (SES)
China National Center for Cardiovascular Diseases, Cardiovascular Institute & Fuwai Hospital
Beijing, Beijing Municipality, China
RECRUITINGInstitute of cardiovascular diseases & Fuwai hospital
Beijing, Beijing Municipality, China
RECRUITINGComposite of major adverse cardiac or cerebrovascular events (MACCE) including death, myocardial infarction, stroke and/or repeat revascularization.
Time frame: 1 year
Overall MACCE rate.
Time frame: 30 days after procedure and 2 years after enrollment
Cardiac death.
Time frame: 30 days after procedure, 1 and 2 years after enrollment
Documented myocardial infarction.
Time frame: 30 days after procedure, 1 and 2 years after enrollment
Target lesion revascularization.
Time frame: 30 days after procedure, 1 and 2 years after enrollment
Recurrence of Angina.
Time frame: 1 and 2 years after enrollment
Cost-effectiveness analysis.
Time frame: 1 and 2 years after enrollment
Quality of life.
Time frame: 6 months, 1 and 2 years after enrollment
Rehospitalization.
Time frame: 6 months, 1 and 2 years after enrollment
Stent thrombosis.
Time frame: 30 days after procedure, 6 months, 1 and 2 years after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
TREATMENT
Masking
NONE
Enrollment
480